Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Amortization of Deferred Charges: 2017-2021

Historic Amortization of Deferred Charges for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2021 value amounting to $113,000.

  • Apellis Pharmaceuticals' Amortization of Deferred Charges fell 76.92% to $3,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $113,000, marking a year-over-year decrease of 49.10%. This contributed to the annual value of $113,000 for FY2021, which is 49.10% down from last year.
  • According to the latest figures from FY2021, Apellis Pharmaceuticals' Amortization of Deferred Charges is $113,000, which was down 49.10% from $222,000 recorded in FY2020.
  • Apellis Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $582,043 for FY2018, and its period low was $11,935 during FY2017.
  • Over the past 3 years, Apellis Pharmaceuticals' median Amortization of Deferred Charges value was $222,000 (recorded in 2020), while the average stood at $230,333.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first surged by 4,776.77% in 2018, then crashed by 49.10% in 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $11,935 in 2017, then skyrocketed by 4,776.77% to $582,043 in 2018, then plummeted by 38.84% to $356,000 in 2019, then slumped by 37.64% to $222,000 in 2020, then crashed by 49.10% to $113,000 in 2021.